For our investors

June 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

For our investors

June 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

For our investors

June 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

For our investors

June 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

For our investors

June 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Our future growth and value generation is based on increasing revenues from our two marketed anti-infectives and our innovative pipeline

Investing in Basilea

Growing revenues: we continue to grow revenues from Cresemba and Zevtera, including launches in further markets
Building global brands: we strengthen and fully exploit the commercial potential from our marketed products. Our commercialization partnerships cover more than 100 countries
Solid cash position: allows us to explore opportunities to selectively expand our pipeline through in-licensing and internal research and development
Growth potential: we are focused on advancing and expanding our R&D portfolio to create sustainable shareholder value

Current presentation

Updated May 20, 2025

Download

Full-Year Report 2024

Download English
Download German

Report Archive

Highlights | Full-Year Report 2024

Play

Events and presentations

Feb 17. 2026

2025 Full-year results and publication of full-year report 2025

Nov 09. 2025 - Nov 12. 2025

Palm Beach Gardens, FL, United States

UBS Global Healthcare Conference

Sep 22. 2025 - Sep 23. 2025

Zürich, Switzerland

HBM Biopharma Summit 2025

Sep 22. 2025

Munich, Germany

Baader Investment Conference 2025

Sep 16. 2025

Stockholm, Sweden

Pareto Securities’ 16th Annual Healthcare Conference 2025

Archive

Annual General Meeting

Apr 16. 2025, 14:00 CEST

Congress Center Basel (CCB) in Basel, Switzerland

2025 Annual General Meeting of Shareholders

Downloads

Show more Show less

Archive

Analyst coverage

The analysts listed on this page have published reports or commentary on Basilea; there may be other analysts who have published reports or commentary that are not referenced here. Please note that any opinions, estimates or forecasts regarding Basilea's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Basilea or its management. Basilea does not by its reference on this website imply any endorsement of or concurrence with such information, conclusions or recommendations.

FIRM	ANALYST
Baader Helvea AG	Thomas Meyer
Bryan Garnier & Co.	Bruno Bulic
Calvine Partners LLP	Brian White
Edison Investment Research Ltd.	Jyoti Prakash
H. C. Wainwright & Co.	Raghuram Selvaraju
Kepler Cheuvreux	Christophe Dombu
Pareto Securities AB	Chien-Hsun Lee & Dan Akschuti
Zürcher Kantonalbank	Laurent Flamme

Share information

Convertible bonds

In July 2020, Basilea issued CHF 97.085 million convertible bonds due 2027 ("New Bonds", ISIN: CH0554992062; SSN: 55'499'206) and repurchased CHF 47.085 million of its CHF 200 million existing convertible bonds due 2022 ("Existing Bonds", ISIN: CH0305398148; SSN: 30'539'814). Through these transactions, the Company significantly improved its debt maturity structure. By December 2022, Basilea had repaid and cancelled the 2022 convertible bonds in full.

Sustainability (ESG)

At Basilea, we have performed a materiality analysis in 2023 that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model. These material topics form the basis of our ESG strategy. They will be key for the setting of goals and are at the core of our future ESG-related reporting. In 2024, we further developed our ESG strategy by defining KPIs for the individual focus topics.

Key elements of Basilea's ESG strategy 2024